Tanha K, Mottaghi A, Nojomi M, Moradi M, Rajabzadeh R, Lotfi S, Janani L (2021) Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses. J Ovarian Res 14(1):153. https://doi.org/10.1186/s13048-021-00911-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Center 2(1):1–9. https://doi.org/10.1016/j.jncc.2022.02.002

Article  Google Scholar 

Konstantinopoulos PA, Matulonis UA (2023) Clinical and translational advances in ovarian cancer therapy. Nature cancer 4(9):1239–1257. https://doi.org/10.1038/s43018-023-00617-9

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  Google Scholar 

Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D (2019) Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules 9(12):789. https://doi.org/10.3390/biom9120789

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das T, Anand U, Pandey SK, Ashby CR Jr, Ashby CR Jr, Assaraf YG, Chen ZS, Dey A (2021) Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates: Rev Commentaries Antimicrobial Anticancer Chemother 55:100754. https://doi.org/10.1016/j.drup.2021.100754

Article  CAS  Google Scholar 

Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N (2018) Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS One 13(6):e0198203. https://doi.org/10.1371/journal.pone.0198203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu J, Hu F, Zhu Q, Li X, Ren H, Fan S, Qian B, Zhai B, Yang D (2020) PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. Nanoscale Res Lett 15(1):59. https://doi.org/10.1186/s11671-019-3228-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Zhu M, Feng Y, Tang Q, Xu M (2020) The multidrug resistance can be reversed for the decrease of P-gp and LRP by inhibiting PI3K/Akt/NF-κB signal pathway in nasopharynx carcinoma. Bioscience reports 40(5):BSR20190239. https://doi.org/10.1042/BSR20190239

Tabata M, Tsubaki M, Takeda T, Tateishi K, Tsurushima K, Imano M, Satou T, Ishizaka T, Nishida S (2020) Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells. BMC Complement Med Ther 20(1):84. https://doi.org/10.1186/s12906-020-2879-8

Article  PubMed  PubMed Central  Google Scholar 

Niu X, Wu T, Yin Q, Gu X, Li G, Zhou C, Ma M, Su L, Tang S, Tian Y, Yang M, Cui H (2022) Combination of paclitaxel and PXR antagonist SPA70 reverses paclitaxel-resistant non-small cell lung cancer. Cells 11(19):3094. https://doi.org/10.3390/cells11193094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caner A, Asik E, Ozpolat B (2021) SRC signaling in cancer and tumor microenvironment. Adv Exp Med Biol 1270:57–71. https://doi.org/10.1007/978-3-030-47189-7_4

Article  CAS  PubMed  Google Scholar 

Gür B, Külcü Sarıkaya N, Sünnetçi Akkoyunlu D (2023) Integrated analysis of differentially expressed genes implicated in ovarian cancer progression. Turkish J Obstetrics Gynecol 20(4):275–284. https://doi.org/10.4274/tjod.galenos.2023.65072

Article  Google Scholar 

Kadife E, Chan E, Luwor R, Kannourakis G, Findlay J, Ahmed N (2019) Paclitaxel-induced src activation is inhibited by dasatinib treatment, independently of cancer stem cell properties, in a mouse model of ovarian cancer. Cancers 11(2):243. https://doi.org/10.3390/cancers11020243

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M (2017) Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol Oncol 144(3):621–630. https://doi.org/10.1016/j.ygyno.2016.12.016

Article  CAS  PubMed  Google Scholar 

Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ (2014) A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 14:681. https://doi.org/10.1186/1471-2407-14-681

Article  PubMed  PubMed Central  Google Scholar 

Wang X (2020) Pleiotrophin: activity and mechanism. Adv Clin Chem 98:51–89. https://doi.org/10.1016/bs.acc.2020.02.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao Y, Rao C, Zheng G, Wang S (2019) Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/pleiotrophin axis. Oncol Rep 42(1):131–141. https://doi.org/10.3892/or.2019.7136

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T (2021) Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer 124(5):896–900. https://doi.org/10.1038/s41416-020-01200-0

Article  CAS  PubMed  Google Scholar 

Ganguly D, Schmidt MO, Coleman M, Ngo TC, Sorrelle N, Dominguez ATA, Murimwa GZ, Toombs JE, Lewis C, Fang YV, Valdes-Mora F, Gallego-Ortega D, Wellstein A, Brekken RA (2023) Pleiotrophin drives a prometastatic immune niche in breast cancer. J Exp Med 220(5):e20220610. https://doi.org/10.1084/jem.20220610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu C, Wang Y, Yuan Q, Wang W, Chi C, Zhang Q, Zhang X (2019) Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer. J Cell Mol Med 23(3):2077–2082. https://doi.org/10.1111/jcmm.14116

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diamantopoulou Z, Kitsou P, Menashi S, Courty J, Katsoris P (2012) Loss of receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) promotes prostate cancer metastasis. J Biol Chem 287(48):40339–40349. https://doi.org/10.1074/jbc.M112.405852

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z, Min D (2017) Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget 8(38):63857–63870. https://doi.org/10.18632/oncotarget.19148

Article  PubMed  PubMed Central  Google Scholar 

Pathak K, Pathak MP, Saikia R, Gogoi U, Sahariah JJ, Zothantluanga JH, Samanta A, Das A (2022) Cancer chemotherapy via natural bioactive compounds. Curr Drug Discov Technol 19(4):e310322202888. https://doi.org/10.2174/1570163819666220331095744

Article  CAS  PubMed  Google Scholar 

Wang J, Li D, Zhao B, Kim J, Sui G, Shi J (2022) Small molecule compounds of natural origin target cellular receptors to inhibit cancer development and progression. Int J Mol Sci 23(5):2672. https://doi.org/10.3390/ijms23052672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long G, Zhao C, Zhao P, Zhou C, Ntirenganya E, Zhou Y (2020) Transcriptomic response to cold of thermophilous medicinal plant Marsdenia tenacissima. Gene 742:144602. https://doi.org/10.1016/j.gene.2020.144602

Article  CAS  PubMed  Google Scholar 

Kong QW, Yang J, Li D, Ding YW, Hu YJ, Xue XC, Shi MZ, Jiang B, Zhou YY, Zhang M, Hu JD, Guo C, Chen JJ, Han YL (2023) Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. J Ethnopharmacol 300:115728. https://doi.org/10.1016/j.jep.2022.115728

Article